Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.

University of Pittsburgh Schools of the Health Sciences

Serotonin Receptor: A Rheostat In Brain For Emotion That May Be Linked To Depression

Amygdala’s response is regulated by a specific serotonin receptor in brain stem

PITTSBURGH, October 1, 2006 — Although drugs that target the brain’s serotonin system are widely used to treat depression, the basic biological mechanism by which they help to alleviate symptoms is poorly understood. Now, new University of Pittsburgh research suggests these drugs work by acting on a specific serotonin receptor called the 5-HT1A autoreceptor, which the study’s investigators found plays a key role in regulating the response of the amygdala.

The findings, published in the journal Nature Neuroscience, also provide a model of how specific changes in 5-HT1A autoreceptors and associated amygdala reactivity may impact a person’s risk for developing depression. Much like a rheostat, these serotonin receptors regulate the brain’s emotional responses and may contribute to one’s vulnerability for depression and other psychiatric disorders.

The amygdala is a critical component of brain circuitry that processes clues from the environment about potential threats and generates appropriate behavioral and physiological responses – such as the “fight or flight” response – to these challenges. Research has indicated that depression and other mood disorders, such as anxiety, are associated with emotional brain circuitry problems involving the amygdala.

The 5-HT1A autoreceptor is located on the surface of serotonin neurons, which are responsible for producing the serotonin neurotransmitter and delivering it to several areas of the brain, including the amygdala. The effect serotonin release has is varied and complex, due to the number of different serotonin receptors found in these brain regions. In contrast, the 5-HT1A autoreceptor on serotonin neurons in the brain stem is rather uniform: it reduces the neuron’s activity and its subsequent release of serotonin to downstream targets, a process called negative feedback inhibition. As more serotonin is released and becomes available in the brain, the neurotransmitter also acts on these 5-HT1A autoreceptors, which in turn work to reduce serotonin release.

In brain imaging studies of 20 normal subjects, the team of investigators found that individuals who had higher concentrations of the 5-HT1A autoreceptor, as assessed by positron emission tomography (PET), also had significantly reduced activity in their amygdala, which was measured by functional magnetic resonance imaging (fMRI). Moreover, the concentration of the 5-HT1A autoreceptor accounted for 30 to 44 percent of the differences in the reactivity of the amygdala among individuals.

“There’s a significant inverse relationship between the density of the 5-HT1A autoreceptor and the amygdala’s reactivity to threatening stimuli, and this mechanism appears to be reflecting the effects of the 5-HT1A on the negative feedback loop that controls the release of serotonin,” said study leader Ahmad R. Hariri, Ph.D., assistant professor of psychiatry and director of the Developmental Imaging Genetics Program at the University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic.

“This observation could be important in understanding a key molecular pathway that may make some people more vulnerable for developing depression or other psychiatric disorders. In our normal subjects, we saw a pattern that suggests the reactivity of the amygdala is regulated by the capacity for negative feedback regulation of serotonin release through the 5-HT1A autoreceptor. Moreover, the pattern suggests that higher levels of serotonin, associated with reduced autoreceptor density and negative feedback, is linked with greater amygdala reactivity,” he added.

The study is one of the few to collect data in research subjects using these two different imaging methods, allowing for more complete interpretations to be drawn about the relationship between molecular changes in the brain and differences in behavior.

In earlier studies, Dr. Hariri and colleagues established a brain basis for a gene variant and its relationship to behavior, finding greater amygdala reactivity in people carrying a form of a gene that leads to reduced expression of the serotonin transporter, who, because of this variation, are more vulnerable to developing depression in the face of stressful and difficult life circumstances. Recently, other researchers have noted that this same genetic variation is associated with reduced 5-HT1A density. Moreover, alterations in 5-HT1A autoreceptor density and amygdala reactivity have been documented in depression, and studies suggest that the class of drugs known as selective serotonin reuptake inhibitors (SSRIs) may evoke an antidepressant effect by acting on both the 5-HT1A autoreceptor and amygdala reactivity. Taken together, Dr. Hariri’s latest findings may be important for understanding the molecular mechanisms underlying the effects of the serotonin transporter gene variation on amygdala reactivity.

“Antidepressants, especially the SSRIs, which increase the availability of serotonin, may actually be working by shifting the availability of 5-HT1A autoreceptors and, as a consequence, modulating the reactivity of the amygdala. Such shifts may drive the improvements in depressed mood and affect that result from SSRI treatment,” explained Dr. Hariri, who plans to conduct additional studies in both healthy volunteers and patients with depression in order to better understand the specific biological pathways that contribute to risk for the condition as well as predict treatment response.

Others who contributed to this research include Patrick M. Fisher, Scott K. Ziolko, Julie C. Price, Ph.D., of the University of Pittsburgh School of Medicine; and Carolyn C. Meltzer, M.D., now at Emory University.

The research was supported by the National Institute of Mental Health of the National Institutes of Health and the National Alliance for Research on Schizophrenia and Depression.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

Pittsburgh, PA, USA |